Navigation Links
Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
Date:3/28/2011

NUTLEY, N.J., March 28, 2011 /PRNewswire/ -- Roche announced today that Janet Hammond, MD, Ph.D., has joined the company as Vice President, Translational Medicine – Virology in Pharmaceutical Research and Early Development (pRED). In her new role, Janet will report to Jacques Banchereau, Ph.D., Discovery and Translational Area (DTA) Head for Inflammation and Virology, and Chief Scientific Officer at Nutley, and be responsible for driving strategy and implementation of early clinical development for the Virology DTA.

Prior to Roche, Janet served as Chief Medical Officer and Senior VP of Global Medical Affairs at Valeant Pharmaceuticals International where she was responsible for medical affairs and pharmacovigilence activities worldwide. As Chair of the Global Safety Board, Janet was also responsible for ensuring patient, clinical trial and product safety. Other industry positions include: Bristol-Myers Squibb, where as Group Director, Global Clinical Research, Virology and Infections Diseases, she was medical lead for the Early Clinical research team for HIV Early Development and Virology Life Cycle management; and GlaxoSmithKline, where she served as Head of Clinical Drug Discovery Virology, responsible for developing a new department as well as medical strategy, IND submissions and clinical development of small molecules and vaccines.

"Janet's background and experience will be a great addition to our efforts to drive Translational Medicine as well as Virology within Roche as we continue our quest to find new and more effective approaches to drug development, ultimately providing better options for patients," said Jacques Banchereau.

"I am delighted to be joining Roche. The company is on the cutting edge of research in the areas of virology and translational medicine, and I am very excited to be able to be part of an impressive team of people who are striving to develop new approaches for the treatment of patients with infectious diseases," said Hammond.

With an impressive 13-year career in the pharmaceutical industry, and a broad academic background in several medical areas, Janet has made numerous contributions to the field. These include: three New Drug Applications (NDA) and Marketing Authorization Application (MAA) submissions, more than 10 supplemental NDAs, and project lead in translational medicine on more than 10 Investigational New Drug (IND) submissions. In addition, she has been involved in launch preparations for three new drugs, and managed the integration and development of new departments as a result of major company acquisitions.

Janet received her MD and Ph.D. degrees from the University of Cape Town, South Africa and an ScM in Clinical Investigation from Johns Hopkins University. Currently, she is an adjunct faculty member at UCLA and attending physician at the West Los Angeles Veterans Administration Hospital.

She is also a member of the College of Medicine of South Africa, International Society of Infectious Diseases, Infectious Diseases Society of America and Southern African Critical Care Society. Janet, a reviewer for Lancet and the European Journal of Medical Microbiology, has authored more than 45 publications and is a sought after presenter at scientific meetings. In addition, Janet has received numerous awards and honors during her career.

Janet is married to Peter Potgieter MD, Ph.D. and will be relocating to Nutley from southern California.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium
2. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
3. Mr. Robert Andrews Joins Asymchem Life Science (Tianjin) Co. Ltd. as Vice President of Quality Assurance
4. Veteran Executive Ron Wall Joins Advanstar Communications as Executive Vice President, Pharmaceutical/Science
5. Former PayPal, Palantir Executive Jason Portnoy Joins Practice Fusion as CFO
6. Medical Devices and Diagnostics Analyst Joins MLV to Further Expand its Coverage of the Life Sciences Sector
7. Ultrasound Industry Expert, Chris Daft, Joins Samplify Systems
8. Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience
9. Josephine Martin Joins PhRMA as Exec VP of Public Affairs
10. Elka Nir Joins VisionCare Board of Directors
11. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
Breaking Medicine News(10 mins):